The prediction of CGPII from triterpenoids of Ganoderma lucidum such as ganoderic acids is supported by Zhang et al., where triterpenoids exhibit nerve growth factor or brain-derived neurotrophic factor activities in vitro, which has the therapeutic potential in neurodegenerative diseases [81]. This evidence concerns the gene BDNF and neurodegenerative disease.